This family protocol summary provides a general overview of the Children's Oncology Group ANBL1232. It tells who is eligible and gives basic information about the study. More details about the study are in the consent form and protocol. You can get these from your oncologist.

ANBL1232 is a Phase 3 clinical trial. A trial is another word for a study. This study (clinical trial) is a therapeutic clinical trial. That means it is done to learn more about how well treatments work and the side effects of the treatments. The purpose of a Phase 3 trial is to learn if a new treatment that is known to work in treating a type of cancer is better in some way than the standard treatment. For example, does it have better cure rates, longer control of disease, fewer or less serious side effects, or fewer days in the hospital?

In most clinical trials, we will not know which treatment is better until all of the children taking part in the trial have completed treatment and have been followed for several years. If one of the treatments is found to be better or safer than the others while the trial is still on-going, the trial will be stopped. All children still in the trial will be given the treatment with the best results when possible.

It is important to understand that participating in a clinical trial is entirely voluntary. The decision about whether or not to participate will not affect the care provided by the health care team in any way. You can find additional information about participation in clinical trials at Always discuss any questions that you may have with your health care team.

Study Number


Study Title

Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma

Study Opening Date

ANBL1232 opened on 7/28/2014. The study team plans to enroll up to 621 patients. It is expected that this study will remain open until the summer of 2019.

General Patient Eligibility

There are 3 groups of patients who are eligible for treatment on this protocol:

Group A:

Group B:

Group C:

Some patients may also have the following risk factors:
  • The tumor involves the liver, causing the liver to be large
  • The tumor is causing symptoms
  • The tumor is made up of "unfavorable" biology features

Please consult your doctor to determine whether you or your child may participate in this study.

General Background and Treatment

The goal of this study is to see if non-high-risk neuroblastoma can be treated without surgery or by changing the amount of chemotherapy given and still get very good results.

Group A

Standard therapy for Group A patients in the past would be surgery to take the tumor out. Recent studies have shown that these tumors will often become smaller or completely go away on their own without surgery.

In this study:

Group B

Standard therapy for Group B patients in the past would be to start chemotherapy and/or perform surgery to remove the tumor.

In this study:

Group C

Standard therapy for Group C patients depends on whether or not they have symptoms, and whether the tumor cells have "favorable" or "unfavorable" biology features.

It is standard for patients without symptoms and with "favorable" biology features to be observed without treatment. It is standard for patients with symptoms or with "unfavorable" biology features to be given chemotherapy. The amount of chemotherapy given depends on the tumor response to therapy.

Recent studies show that very young patients whose cancer involves the liver or who have symptoms caused by the cancer have a higher chance of having complications. In this study, we hope that by starting chemotherapy immediately for these patients, we can prevent the complications and get better results.

A symptom score system will be used to decide on the timing and amount of chemotherapy given. The scoring system will help improve treatment since the amount of chemotherapy given will be decided by the patient's response to therapy and their own symptom score.

In this study:

The amount of chemotherapy given depends on how well the tumor responds to therapy and if symptoms go away. The use of the symptom score is to see if we can give a more personalized amount of chemotherapy.

Risks and Side Effects

Chemotherapy can cause side effects during and after treatment. All patients will be closely monitored for possible side effects of the medicines. All risks and side effects will be explained by your treatment team during the consent process. They can answer any questions that you may have about giving permission for your child to be in the clinical trial or other aspects of care. Please refer to the consent form for a detailed explanation of the side effects associated with the treatment on this study.

Contact Information

Your child's oncologist and nurses are the best sources for further information.

Study Chair



Initial development Name Date
Written by Wendy Fitzgerald, RN September 29, 2015
Reviewed/approved by (PI) Holly Meany, MD August 16, 2016
Ongoing review
Reviewed and updated by Wendy Fitzgerald, RN, PNP-BC, CPON March 9, 2017
February 8, 2018
October 22, 2018

© The Children's Oncology Group
The information and content provided on this website is made available for informational purposes only for children and their families affected by cancer. While the Children's Oncology Group strives to provide accurate and up-to-date information, the information may be out of date or incomplete in certain respects. Please do not rely on this information and seek the care of a qualified medical professional if you have questions regarding a specific medical condition, disease, diagnosis or symptom. The information and content presented herein is not intended to replace the independent clinical judgement, medical advice, screening, health counseling, or other intervention performed by your (or your child's) health care provider. Please contact "911" or your emergency services if this is a health emergency. No endorsement of any specific tests, products, or procedures is made herein.